Monograph

S01AE07 - Moxifloxacin

Not porphyrinogenic

Side effects

Plasma concentrations are well below 1 µM (SPC) and hepatic exposure in therefore insignificant.

Rationale

Administered locally in the eye and systemic exposure is insignificant.

Chemical description

Fluoroquinolone antibiotic

Therapeutic characteristics

Moxifloxacin eye drops are used in the treatment of bacterial conjunctivitis.

Hepatic exposure

Moxifloxacin is metabolized mainly via sulfate or glucuronide conjugation, while the rest is excreted as the unchanged form. It is probably CYP450 independent (SPC).

References

#	Citation details	PMID
*	Summary of Product Characteristics
1.	The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Moxivig.

Citation details

PMID

Summary of Product Characteristics

The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Moxivig.

Similar drugs

Explore alternative drugs in similar therapeutic classes S01A / S01AE or go back.

Tradenames and packages

From some sources, we get a list of packages (United Kingdom, Ireland, Estonia). Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway). What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names are the searchable terms. The gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Netherlands

Moxifloxacine · Moxifloxacine Stulln 5 mg/ml oogdruppels, oplossing · Moxifloxacine Stulln zonder conserveermiddel 5 mg/ml, oogdruppels, oplossing in verpakking voor éénmalig gebruik · Vigamox · Vigamox 5 mg/ml oogdruppels, oplossing

Belgium